SAMANTREE-MEDICAL
14.5.2019 12:43:07 CEST | Business Wire | Press release
SamanTree Medical, committed to reducing the need for cancer surgery re-operation particularly in breast surgery, announced today the successful closing of its CHF 9.5 million Series A financing. Proceeds will be used to commercialize the patented Histolog™ system, notably the recently CE mark Histolog™ Scanner v2, for enabling precise tumor removal at first surgery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005476/en/
Panakès Partners, the Medtech European leading venture capital mixing strong corporate and investment expertise, has led this round, alongside the Sioux Tech Fund, the venture arm of Sioux Technologies, a company with expertise in high-tech manufacturing, software development and data analytics. Existing shareholders and new investors BOM Brabant Ventures and btov Partners were participating as well.
“The timing is impeccable with the recently awarded European project, we are combining the right supports for executing on our mission to bring the gold standard in the Operating Room” said CEO and Co-Founder Bastien Rachet. The European Innovation Council awarded SamanTree Medical with EUR 2.3 million grant in September 2018, via its H2020 SME’s Instrument Program.
More than 500,000 lumpectomies are performed annually in the USA and Europe alone and up to 25% require re-operation. Additional operation is a burden for the patient and it increases the stress relative to the treatment; it also results in annual costs of $2.7 billion. Surgeons face a difficult trade-off: maximize confidence in removal of the entire tumor and minimize removal of healthy tissue. The “Gold Standard” for margin assessment is histopathology microscopy – these laboratory results, however, aren’t available until days after surgery. Surgeons need faster support for margin assessment in the operating room, ideally in real-time and with accuracy comparable to this “Gold Standard”.
SamanTree’s Histolog™ is the only solution that enables a global mapping of a lumpectomy for full margin control with histology-grade confidence in few minutes before closing the incision. With this innovative and highly practical imaging modality, the clinician is one touch-on-the-screen away from visualizing cancerous cell on a surgical specimen immediately during surgery. Enhancing the decision-making process during the surgery, this solution carries the promise of a better patient care, by increasing the confidence in a complete tumor removal at first surgery.
About SamanTree Medical
SamanTree Medical, a spin-off
company from the Swiss Federal Institute of Technology (EPFL), develops
disruptive imaging modalities and data analytic solutions for improving
cancer treatment care. Founded in December 2014, SamanTree is
headquartered in Lausanne, Switzerland. www.samantree.com
About Panakès Partners
Panakès Partners is a Venture Capital
investor that finances medical companies, early stage startups and SMEs,
with extremely promising products and great ambition, in Europe and
Israel, improving both patient outcomes and healthcare economics.
Investments focus on the medical device, diagnostics and healthcare IT
fields. Panakès Partners is headquartered in Milan, Italy.
www.panakes.it
/ Contact: contact@panakes.it
About the Sioux Tech Fund
The investment fund of high-tech
company Sioux Technologies, together with regional and European partners
(such as the Brabant Development Agency and the European Angel Fund),
invests in promising technical start-ups. This gives innovative ideas a
chance for faster development in terms of technological progress and
faster market introduction.
www.sioux.eu
/ Contact: info@sioux.eu
About BOM Brabant Ventures
BOM (the Brabant Development
Agency) works together with entrepreneurs to create a strong,
sustainable, and future-proof Brabant economy. BOM uses the Brabant
Ventures label to focus, using knowledge and capital, on the accelerated
and future-proof growth of ambitious Brabant startups and scaleups in
the high-tech systems and software, agri-food, life sciences & health,
maintenance, supply chain, and bio-based economy top industries.
www.bom.nl
/ Contact: info@bom.nl
SamanTree Medical has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No.823284.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005476/en/
Contact:
For more information regarding this press release, please contact: Florence Besnier, Executive Office Manager +41 21 625 09 40 Email: info@samantree.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Telekom Srbija Raises €1.95 Billion Through Landmark Eurobond Transaction, Attracting Record Demand from Global Investors12.5.2026 12:09:00 CEST | Press release
The largest corporate bond issuance from the region attracted nearly USD 14 billion in demand from around 300 global institutional investors, marking a milestone moment for Southeast European capital markets. Telekom Srbija has successfully completed its second international corporate bond issuance, raising approximately €1.95 billion through a multi-tranche offering of senior unsecured notes denominated in U.S. dollars and euros. The transaction generated exceptional investor interest, attracting total demand of USD 13.87 billion from approximately 300 leading international institutional investors, making it the largest corporate bond issuance ever executed in the Southeast / Central and Eastern Europe region, as well as one of the most heavily oversubscribed corporate transactions across emerging markets globally during 2025 and 2026. The issuance attracted participation from many of the world’s most prominent pension funds, insurance companies, sovereign-affiliated investors, and gl
Venture Global Announces LNG Purchase Agreements with TotalEnergies and Vitol12.5.2026 12:00:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of two binding agreements with TotalEnergies and Vitol for the purchase of additional U.S. liquefied natural gas (LNG) from Venture Global. Venture Global announced a new, binding agreement with TotalEnergies for the purchase of approximately 0.85 MTPA of LNG from Venture Global for approximately five years commencing in 2026. Separately, Venture Global and Vitol agreed to increase their existing five-year binding LNG agreement to 1.7 MTPA, up from 1.5 MTPA previously agreed and announced in March 2026. Both agreements will be supplied from Venture Global’s portfolio. “Venture Global is proud to deepen our partnerships with premier global energy companies like Vitol and TotalEnergies,” said Venture Global CEO Mike Sabel. “These agreements reflect the continued confidence and trust in our ability to deliver reliable, low-cost U.S. LNG to global markets quickly and at scale as demand for energy security continues to grow. By
L&T Technology Services and Emerson Announce a Global Cooperation and Strategic Engagement to Drive Innovation in Engineering Excellence12.5.2026 11:30:00 CEST | Press release
Partnership in its Sustainability segment brings together LTTS’ engineering capabilities and Emerson’s NI test platform to accelerate system integration and product development across multiple industries L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital and Engineering R&D services, today announced a strategic global partnership with Emerson (NYSE: EMR), a global automation leader and provider of advanced test and measurement solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511346343/en/ L&T Technology Services and Emerson announce strategic global partnership. Seen in the picture: Senior leaders and delegates from L&T Technology Services and Emerson’s Test & Measurement business, including the NI leadership team. Under this engagement, LTTS will serve as a global System Integrator and technology development partner, supporting the design, deployment and lifecycle enablement of adva
Goldman Sachs Alternatives Acquires FGI Worldwide12.5.2026 11:00:00 CEST | Press release
Transaction Accelerates FGI’s Growth and Expands Product Offering FGI Worldwide LLC (“FGI” or the “Company”), a leading provider of working capital financing and trade credit insurance solutions, today announced it has been acquired by the Private Equity business within Goldman Sachs Alternatives. Over its 25-year history, FGI has established a strong reputation as a leader and innovator in asset-based lending and risk mitigation, specializing in multi-jurisdictional working capital solutions that support businesses with flexible financing to drive domestic and global expansion. The acquisition enables FGI to accelerate its growth and expand its suite of financing, risk and Insurtech solutions for clients. In conjunction with the transaction, Sami Altaher, Co-Founder and President of FGI, succeeds David DiPiero as Chief Executive Officer, marking the next chapter in the Company’s evolution. “We are grateful to our team, customers, partners and investors who have made this milestone pos
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets12.5.2026 10:45:00 CEST | Press release
“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511305446/en/ Antonio Petralia, CEO of Eurosets; Sahara Romero, patient; dr. Mario Andrés Mercado Díaz, Intensive care specialist at the Clínica Shaio in Bogotá; Estefanía Giraldo Bejarano, specialist ECMO nurse at the Clínica Shaio in Bogotá Sahara has lived with a serious heart condition since early adolescence. The first signs of heart failure appeared when she was eleven. “When I was doing simple activities, like gymnastics lessons, I got very tired and experienced pain in my chest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom